QUIDELORTHO CORP Increase (Decrease) in Accounts Receivable
QUIDELORTHO CORP (QDEL) reported Increase (Decrease) in Accounts Receivable of -$62.90 million for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- QUIDELORTHO CORP increase (decrease) in accounts receivable for the quarter ending 2026-06-28 was -$8.90M.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for the quarter ending 2026-03-29 was -$54.00M.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for the quarter ending 2025-12-28 was $28.80M, a 1209.09% increase year-over-year.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for the quarter ending 2025-09-28 was $113.40M, a 583.13% increase year-over-year.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for fiscal 2025 was $117.50M.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for fiscal 2024 was -$5.40M.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for fiscal 2023 was -$160.00M.
- QUIDELORTHO CORP increase (decrease) in accounts receivable for fiscal 2023 was -$150.20M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-28 | -$8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$62.90M 10-Q · filed 2026-08-07 | -$34.10M derived: sum of 3 quarters · filed 2026-08-07 | $79.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-29 | -$54.00M 10-Q · filed 2026-05-06 | -$25.20M derived: sum of 2 quarters · filed 2026-05-06 | $88.20M derived: sum of 3 quarters · filed 2026-05-06 | $65.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-28 | $28.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $142.20M derived: sum of 2 quarters · filed 2026-02-19 | $119.70M derived: sum of 3 quarters · filed 2026-08-07 | $117.50M 10-K · filed 2026-02-19 |
| 2025-09-28 | $113.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $90.90M derived: sum of 2 quarters · filed 2026-08-07 | $88.70M 10-Q · filed 2025-11-06 | $90.90M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-29 | -$22.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$24.70M 10-Q · filed 2026-08-07 | -$22.50M derived: sum of 3 quarters · filed 2026-08-07 | -$5.90M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-30 | -$2.20M 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $16.60M derived: sum of 3 quarters · filed 2026-05-06 | $18.80M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-29 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $18.80M derived: sum of 2 quarters · filed 2026-02-19 | $21.00M derived: sum of 3 quarters · filed 2026-02-19 | -$5.40M 10-K · filed 2026-02-19 |
| 2024-09-29 | $16.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.80M derived: sum of 2 quarters · filed 2025-11-06 | -$7.60M 10-Q · filed 2025-11-06 | -$43.50M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$24.20M 10-Q · filed 2025-08-06 | -$60.10M derived: sum of 3 quarters · filed 2026-02-19 | $30.30M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$26.40M 10-Q · filed 2025-05-08 | -$62.30M derived: sum of 2 quarters · filed 2026-02-19 | $28.10M derived: sum of 3 quarters · filed 2026-02-19 | $800.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$35.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $54.50M derived: sum of 2 quarters · filed 2026-02-19 | $27.20M derived: sum of 3 quarters · filed 2026-02-19 | -$160.00M 10-K · filed 2026-02-19 |
| 2023-10-01 | $90.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $63.10M derived: sum of 2 quarters · filed 2024-11-08 | -$124.10M 10-Q · filed 2024-11-08 | -$92.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | -$27.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$214.50M 10-Q · filed 2024-08-01 | -$183.10M derived: sum of 3 quarters · filed 2025-02-27 | -$132.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | -$187.20M 10-Q · filed 2024-05-09 | -$155.80M derived: sum of 2 quarters · filed 2025-02-27 | -$105.10M derived: sum of 3 quarters · filed 2025-02-27 | -$528.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-01-01 | $31.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $82.10M derived: sum of 2 quarters · filed 2025-02-27 | -$341.70M derived: sum of 3 quarters · filed 2025-02-27 | -$150.20M 10-K · filed 2025-02-27 |
| 2022-10-02 | $50.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$373.10M derived: sum of 2 quarters · filed 2023-11-02 | -$181.60M 10-Q · filed 2023-11-02 | -$139.00M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-07-03 | -$423.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$232.30M 10-Q · filed 2023-08-09 | -$189.70M derived: sum of 3 quarters · filed 2024-08-01 | $100.00M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-04-03 | $191.50M 10-Q · filed 2023-05-04 | $234.10M derived: sum of 2 quarters · filed 2024-08-01 | $523.80M derived: sum of 3 quarters · filed 2024-08-01 | |
| 2022-01-02 | $42.60M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01 | $332.30M derived: sum of 2 quarters · filed 2024-08-01 | -$118.90M 10-K/A · filed 2024-08-01 | |
| 2021-10-03 | $289.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$161.50M 10-Q · filed 2022-11-04 | ||
| 2021-07-04 | -$451.20M 10-Q · filed 2022-08-05 | |||
| 2021-01-03 | $402.10M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |